| Aug 6 |
Cellectis GAAP EPS of -$0.28 beats by $0.02, revenue of $9.5M beats by $5.77M
|
| Aug 6 |
Cellectis Provides Financial Results for the Second Quarter 2024
|
| Aug 2 |
Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia
|
| Aug 1 |
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
|
| Jul 25 |
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
|
| Jul 12 |
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
|
| Jul 5 |
Monthly information on share capital and company voting rights
|
| Jun 20 |
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
|
| Jun 18 |
Cellectis Upgraded to Buy: Here's Why
|
| Jun 18 |
Cellectis (CLLS) Upgraded to Buy: Here's Why
|
